Moberg Pharma AB (OSTO:MOB)
kr 10.21 -0.29 (-2.76%) Market Cap: 476.74 Mil Enterprise Value: 171.44 Mil PE Ratio: 0 PB Ratio: 0.53 GF Score: 46/100

Q3 2021 Moberg Pharma AB (publ) Earnings Call Transcript

Nov 09, 2021 / 02:00PM GMT
Release Date Price: kr39.07 (-1.94%)
Operator

Hello, and welcome to Moberg Pharma Q3 report for 2021. (Operator Instructions) Today, I am pleased to present CEO, Anna Ljung. Please begin your meeting.

Anna Ljung;publ;CEO
Moberg Pharma AB

()-

Thank you, and hello, everyone. My name is Anna Ljung. I'm the CEO of Moberg Pharma. And with me today, I also have our VP of Finance, Mark Beveridge. And we're happy to present the Q3 report that was published this morning. You can find the report on our website, and there, you will also find a PowerPoint presentation that I will use throughout this call.

Now start on Page 3 on that presentation is giving that overview of Moberg Pharma. We're a Swedish pharmaceutical company that base our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. And our lead program is MOB-015 against nail fungus. And here, we see that we have the possibility to be -- to become the global market leader within onychomycosis, targeting a global sales potential of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot